![Paul Grant Ellis](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Paul Grant Ellis
Founder at Ellis Bates Financial Solutions Ltd.
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Michael Charles Cope | M | 54 |
Ellis Bates Financial Solutions Ltd.
![]() Ellis Bates Financial Solutions Ltd. Financial ConglomeratesFinance Ellis Bates Financial Solutions Ltd. provides financial intermediary services. The private company is based in Harrogate, UK and has subsidiaries in the United Kingdom. The British company was founded by Paul Grant Ellis and Peter Andrew Bates. Michael Charles Cope has been the CEO of the company since 2008.
Ellis Bates Legal Solutions Ltd.
![]() Ellis Bates Legal Solutions Ltd. Miscellaneous Commercial ServicesCommercial Services Ellis Bates Legal Solutions Ltd. is a British company that provides patent and copyright services. The private company is based in Harrogate, UK and was founded in 2015.
Ellis Bates Wealth Management Ltd.
![]() Ellis Bates Wealth Management Ltd. Financial ConglomeratesFinance Part of Ellis Bates Financial Solutions Ltd., Ellis Bates Wealth Management Ltd. is a British company that provides investment services. The company is based in Harrogate, UK and was founded in 2014. | 16 years |
Peter Andrew Bates | M | 76 |
Ellis Bates Financial Solutions Ltd.
![]() Ellis Bates Financial Solutions Ltd. Financial ConglomeratesFinance Ellis Bates Financial Solutions Ltd. provides financial intermediary services. The private company is based in Harrogate, UK and has subsidiaries in the United Kingdom. The British company was founded by Paul Grant Ellis and Peter Andrew Bates. Michael Charles Cope has been the CEO of the company since 2008.
The Risk Factor Ltd.
![]() The Risk Factor Ltd. Property/Casualty InsuranceFinance The Risk Factor Ltd. provides risk advisory services to the public and corporate sector. It specializes in delivering transparency of the insurance market through qualified risk practitioners working in-house. The company was founded by Mark Webb in April 1994 and is headquartered in Harrogate, the United Kingdom.
Ellis Bates Legal Solutions Ltd.
![]() Ellis Bates Legal Solutions Ltd. Miscellaneous Commercial ServicesCommercial Services Ellis Bates Legal Solutions Ltd. is a British company that provides patent and copyright services. The private company is based in Harrogate, UK and was founded in 2015.
Ellis Bates Wealth Management Ltd.
![]() Ellis Bates Wealth Management Ltd. Financial ConglomeratesFinance Part of Ellis Bates Financial Solutions Ltd., Ellis Bates Wealth Management Ltd. is a British company that provides investment services. The company is based in Harrogate, UK and was founded in 2014. | 13 years |
Elizabeth Clare Mills | F | 51 |
Ellis Bates Financial Solutions Ltd.
![]() Ellis Bates Financial Solutions Ltd. Financial ConglomeratesFinance Ellis Bates Financial Solutions Ltd. provides financial intermediary services. The private company is based in Harrogate, UK and has subsidiaries in the United Kingdom. The British company was founded by Paul Grant Ellis and Peter Andrew Bates. Michael Charles Cope has been the CEO of the company since 2008.
Ellis Bates Wealth Management Ltd.
![]() Ellis Bates Wealth Management Ltd. Financial ConglomeratesFinance Part of Ellis Bates Financial Solutions Ltd., Ellis Bates Wealth Management Ltd. is a British company that provides investment services. The company is based in Harrogate, UK and was founded in 2014.
Ellis Bates Legal Solutions Ltd.
![]() Ellis Bates Legal Solutions Ltd. Miscellaneous Commercial ServicesCommercial Services Ellis Bates Legal Solutions Ltd. is a British company that provides patent and copyright services. The private company is based in Harrogate, UK and was founded in 2015. | 6 years |
Deborah A. O’Neil | M | 53 |
NovaBiotics Ltd.
![]() NovaBiotics Ltd. Pharmaceuticals: MajorHealth Technology NovaBiotics Ltd. operates as a clinical-stage biotechnology firm. It designs and develops antifungal and antibacterial therapeutics for medically unmet fungal, bacterial, and polymicrobial conditions. It offers clinical and preclinical product candidates to treat clinically challenging infections that include NP213 (Novexatin) phase IIb-ready potent topical treatment for fungal nail infections (onychomycosis); NM001 (Lynovex), a dual antibacterial-mucolytic orphan drug candidate in phase IIa clinical evaluation for cystic fibrosis; NP339 (Novamycin), an antifungal peptide agent against Candida spp and other clinically relevant yeasts/moulds; and NP432 (Novarifyn), a peptide antibacterial candidate for multi-drug resistant gram-negative and gram-positive infections. The company was founded by Deborah A. O?Neil in August 2004 and is headquartered in Aberdeen, the United Kingdom. | 20 years |
Jamie Robert Alderson | M | 49 |
Ellis Bates Legal Solutions Ltd.
![]() Ellis Bates Legal Solutions Ltd. Miscellaneous Commercial ServicesCommercial Services Ellis Bates Legal Solutions Ltd. is a British company that provides patent and copyright services. The private company is based in Harrogate, UK and was founded in 2015.
Ellis Bates Wealth Management Ltd.
![]() Ellis Bates Wealth Management Ltd. Financial ConglomeratesFinance Part of Ellis Bates Financial Solutions Ltd., Ellis Bates Wealth Management Ltd. is a British company that provides investment services. The company is based in Harrogate, UK and was founded in 2014. | 4 years |
Alan Earel Cram | M | 51 |
Ellis Bates Wealth Management Ltd.
![]() Ellis Bates Wealth Management Ltd. Financial ConglomeratesFinance Part of Ellis Bates Financial Solutions Ltd., Ellis Bates Wealth Management Ltd. is a British company that provides investment services. The company is based in Harrogate, UK and was founded in 2014.
Ellis Bates Legal Solutions Ltd.
![]() Ellis Bates Legal Solutions Ltd. Miscellaneous Commercial ServicesCommercial Services Ellis Bates Legal Solutions Ltd. is a British company that provides patent and copyright services. The private company is based in Harrogate, UK and was founded in 2015. | 5 years |
Bryan Harvey Bodek | M | 71 |
NovaBiotics Ltd.
![]() NovaBiotics Ltd. Pharmaceuticals: MajorHealth Technology NovaBiotics Ltd. operates as a clinical-stage biotechnology firm. It designs and develops antifungal and antibacterial therapeutics for medically unmet fungal, bacterial, and polymicrobial conditions. It offers clinical and preclinical product candidates to treat clinically challenging infections that include NP213 (Novexatin) phase IIb-ready potent topical treatment for fungal nail infections (onychomycosis); NM001 (Lynovex), a dual antibacterial-mucolytic orphan drug candidate in phase IIa clinical evaluation for cystic fibrosis; NP339 (Novamycin), an antifungal peptide agent against Candida spp and other clinically relevant yeasts/moulds; and NP432 (Novarifyn), a peptide antibacterial candidate for multi-drug resistant gram-negative and gram-positive infections. The company was founded by Deborah A. O?Neil in August 2004 and is headquartered in Aberdeen, the United Kingdom. | 15 years |
Ian Townsend | M | 69 |
NovaBiotics Ltd.
![]() NovaBiotics Ltd. Pharmaceuticals: MajorHealth Technology NovaBiotics Ltd. operates as a clinical-stage biotechnology firm. It designs and develops antifungal and antibacterial therapeutics for medically unmet fungal, bacterial, and polymicrobial conditions. It offers clinical and preclinical product candidates to treat clinically challenging infections that include NP213 (Novexatin) phase IIb-ready potent topical treatment for fungal nail infections (onychomycosis); NM001 (Lynovex), a dual antibacterial-mucolytic orphan drug candidate in phase IIa clinical evaluation for cystic fibrosis; NP339 (Novamycin), an antifungal peptide agent against Candida spp and other clinically relevant yeasts/moulds; and NP432 (Novarifyn), a peptide antibacterial candidate for multi-drug resistant gram-negative and gram-positive infections. The company was founded by Deborah A. O?Neil in August 2004 and is headquartered in Aberdeen, the United Kingdom. | 13 years |
Mark Griffiths | M | - |
The Risk Factor Ltd.
![]() The Risk Factor Ltd. Property/Casualty InsuranceFinance The Risk Factor Ltd. provides risk advisory services to the public and corporate sector. It specializes in delivering transparency of the insurance market through qualified risk practitioners working in-house. The company was founded by Mark Webb in April 1994 and is headquartered in Harrogate, the United Kingdom. | 13 years |
Paul Ian Crapper | M | - |
The Risk Factor Ltd.
![]() The Risk Factor Ltd. Property/Casualty InsuranceFinance The Risk Factor Ltd. provides risk advisory services to the public and corporate sector. It specializes in delivering transparency of the insurance market through qualified risk practitioners working in-house. The company was founded by Mark Webb in April 1994 and is headquartered in Harrogate, the United Kingdom. | 11 years |
Malcolm Barratt-Johnson | M | 61 |
NovaBiotics Ltd.
![]() NovaBiotics Ltd. Pharmaceuticals: MajorHealth Technology NovaBiotics Ltd. operates as a clinical-stage biotechnology firm. It designs and develops antifungal and antibacterial therapeutics for medically unmet fungal, bacterial, and polymicrobial conditions. It offers clinical and preclinical product candidates to treat clinically challenging infections that include NP213 (Novexatin) phase IIb-ready potent topical treatment for fungal nail infections (onychomycosis); NM001 (Lynovex), a dual antibacterial-mucolytic orphan drug candidate in phase IIa clinical evaluation for cystic fibrosis; NP339 (Novamycin), an antifungal peptide agent against Candida spp and other clinically relevant yeasts/moulds; and NP432 (Novarifyn), a peptide antibacterial candidate for multi-drug resistant gram-negative and gram-positive infections. The company was founded by Deborah A. O?Neil in August 2004 and is headquartered in Aberdeen, the United Kingdom. | 4 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Andrew Justin Radcliffe Porter | M | - |
NovaBiotics Ltd.
![]() NovaBiotics Ltd. Pharmaceuticals: MajorHealth Technology NovaBiotics Ltd. operates as a clinical-stage biotechnology firm. It designs and develops antifungal and antibacterial therapeutics for medically unmet fungal, bacterial, and polymicrobial conditions. It offers clinical and preclinical product candidates to treat clinically challenging infections that include NP213 (Novexatin) phase IIb-ready potent topical treatment for fungal nail infections (onychomycosis); NM001 (Lynovex), a dual antibacterial-mucolytic orphan drug candidate in phase IIa clinical evaluation for cystic fibrosis; NP339 (Novamycin), an antifungal peptide agent against Candida spp and other clinically relevant yeasts/moulds; and NP432 (Novarifyn), a peptide antibacterial candidate for multi-drug resistant gram-negative and gram-positive infections. The company was founded by Deborah A. O?Neil in August 2004 and is headquartered in Aberdeen, the United Kingdom. | 12 years |
Statistics
Country | Connections | % of total |
---|---|---|
United Kingdom | 12 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Paul Grant Ellis
- Personal Network